Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | GAPDH | P04406 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13607976 | 0.85 | HPGD (0.58) | HPGDCA1CA2RAB9ASMN1; SMN2 | |
| SCHEMBL8240475 | 0.85 | L3MBTL1 (0.73) | HPGDCA1CA2RAB9ASMN1; SMN2 | |
| SCHEMBL10986259 | 0.84 | MEN1 (0.59) | HPGDCA1CA2RAB9ASMN1; SMN2 | |
| SCHEMBL21342392 | 0.83 | HPGD (0.75) | HPGDRAB9ASMN1; SMN2NPC1ANO1 | |
| SCHEMBL11472205 | 0.83 | HPGD (0.56) | HPGDCA1CA2RAB9ASMN1; SMN2 | |
| SCHEMBL8128592 | 0.82 | CA1 (0.53) | HPGDCA1CA2L3MBTL1LMNA | |
| SCHEMBL934891 | 0.82 | AOC2 (0.64) | HPGDRAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL19133623 | 0.81 | CA1 (0.59) | HPGDCA1CA2RAB9ASMN1; SMN2 | |
| SCHEMBL19387994 | 0.81 | RAB9A (0.58) | HPGDCA1CA2RAB9ASMN1; SMN2 | |
| SCHEMBL26188017 | 0.80 | RAB9A (0.58) | HPGDCA1CA2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7335725-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | CLPTM1, NGLY1, VIP | HPGD 1145/4885CA1 4819/4885CA2 4436/4885 |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | HPGD 1145/4885CA1 4819/4885CA2 4436/4885 |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | HPGD 1145/4885CA1 4819/4885CA2 4436/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | HPGD 3453/4885CA1 2456/4885CA2 4257/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | HPGD 65/4885CA1 2221/4885CA2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.